Nalidixic acid
Neggram (nalidixic acid) is a small molecule pharmaceutical. Nalidixic acid was first approved as Neggram on 1982-01-01. It is used to treat escherichia coli infections, klebsiella infections, proteus infections, salmonella infections, and urinary tract infections in the USA.
Download report
Favorite
Commercial
Therapeutic Areas
Therapeutic Area | MeSH |
|---|---|
| infections | D007239 |
| urogenital diseases | D000091642 |
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
Labels
FDA
EMA
No data
Indications
FDA
EMA
Indication | Ontology | MeSH | ICD-10 |
|---|---|---|---|
| escherichia coli infections | EFO_1001318 | D004927 | B96.20 |
| klebsiella infections | EFO_1001353 | D007710 | — |
| proteus infections | EFO_1001130 | D011512 | — |
| salmonella infections | EFO_1001418 | D012480 | A02.9 |
| urinary tract infections | EFO_0003103 | D014552 | N39.0 |
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
HCPCS
No data
Clinical
Clinical Trials
13 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Liver cirrhosis | D008103 | EFO_0001422 | K74.0 | — | — | — | 3 | — | 3 |
| Migraine disorders | D008881 | EFO_0003821 | G43 | 1 | — | — | 1 | — | 2 |
| Portal hypertension | D006975 | EFO_0000666 | K76.6 | — | — | — | 1 | — | 1 |
| Gastrointestinal hemorrhage | D006471 | K92.2 | — | — | — | 1 | — | 1 |
Indications Phases 3
No data
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Smoking cessation | D016540 | EFO_0004319 | — | 1 | — | — | — | 1 | |
| Asthma | D001249 | EFO_0000270 | J45 | 1 | 1 | — | — | — | 1 |
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Healthy volunteers/patients | — | 2 | — | — | — | — | 2 | ||
| Hypertension | D006973 | EFO_0000537 | I10 | 1 | — | — | — | — | 1 |
| Chest pain | D002637 | HP_0100749 | R07.9 | 1 | — | — | — | — | 1 |
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | NALIDIXIC ACID |
| INN | nalidixic acid |
| Description | Nalidixic acid is a monocarboxylic acid comprising 1,8-naphthyridin-4-one substituted by carboxylic acid, ethyl and methyl groups at positions 3, 1, and 7, respectively. An orally administered antibacterial, it is used in the treatment of lower urinary-tract infections due to Gram-negative bacteria, including the majority of E. coli, Enterobacter, Klebsiella, and Proteus species. It has a role as an antibacterial drug, a DNA synthesis inhibitor and an antimicrobial agent. It is a monocarboxylic acid, a 1,8-naphthyridine derivative and a quinolone antibiotic. It is a conjugate acid of a nalidixic acid anion. |
| Classification | Small molecule |
| Drug class | narcotic agonists/antagonists (normorphine type) |
| Image (chem structure or protein) | |
| Structure (InChI/SMILES or Protein Sequence) | CCn1cc(C(=O)O)c(=O)c2ccc(C)nc21 |
Identifiers
| PDB | — |
| CAS-ID | 389-08-2 |
| RxCUI | 7240 |
| ChEMBL ID | CHEMBL5 |
| ChEBI ID | 100147 |
| PubChem CID | 4421 |
| DrugBank | DB00779 |
| UNII ID | 3B91HWA56M (ChemIDplus, GSRS) |
Target
Agency Approved
No data
Alternate
No data
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 21,310 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
1,531 adverse events reported
View more details
Premium feature
Learn more about premium features at pharmakb.com
Learn more